Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Yamamoto T, Kadoya N, Shirata Y, Kaneta T, Koto M, Umezawa R, Ishikawa Y, Kubozono M, Sugawara T, Matsushita H, Abe K, Takeda K, Jingu K. Yamamoto T, et al. Among authors: shirata y. Ann Nucl Med. 2015 Oct;29(8):666-73. doi: 10.1007/s12149-015-0991-5. Epub 2015 Jun 4. Ann Nucl Med. 2015. PMID: 26040413
Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.
Jingu K, Matsushita H, Takeda K, Umezawa R, Takahashi C, Sugawara T, Kubozono M, Abe K, Tanabe T, Shirata Y, Yamamoto T, Ishikawa Y, Nemoto K. Jingu K, et al. Among authors: shirata y. BMC Cancer. 2012 Nov 22;12:542. doi: 10.1186/1471-2407-12-542. BMC Cancer. 2012. PMID: 23171077 Free PMC article. Clinical Trial.
Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
Yamamoto T, Kadoya N, Shirata Y, Koto M, Sato K, Matsushita H, Sugawara T, Umezawa R, Kubozono M, Ishikawa Y, Kozumi M, Takahashi N, Ito K, Katagiri Y, Takeda K, Jingu K. Yamamoto T, et al. Among authors: shirata y. Radiat Oncol. 2015 Feb 7;10:35. doi: 10.1186/s13014-015-0343-6. Radiat Oncol. 2015. PMID: 25886315 Free PMC article.
Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors.
Yamamoto T, Jingu K, Shirata Y, Koto M, Matsushita H, Sugawara T, Kubozono M, Umezawa R, Abe K, Kadoya N, Ishikawa Y, Kozumi M, Takahashi N, Takeda K, Takai Y. Yamamoto T, et al. Among authors: shirata y. BMC Cancer. 2014 Jun 23;14:464. doi: 10.1186/1471-2407-14-464. BMC Cancer. 2014. PMID: 24957478 Free PMC article.
Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S. Takeda K, et al. Among authors: shirata y. Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105. Radiat Oncol. 2012. PMID: 22770471 Free PMC article.
17 results